Information Provided By:
Fly News Breaks for September 7, 2018
GWPH
Sep 7, 2018 | 07:20 EDT
Morgan Stanley analyst David Lebowitz resumed coverage of GW Pharmaceuticals with an Overweight rating and $197 price target, stating that he expects a strong launch for Epidiolex for Dravet and Lenox-Gastaut syndromes once the DEA has officially rescheduled the marijuana-based therapy as being acceptable for medicinal use. He projects 2019 Epidiolex franchise sales of $72M growing to $1.3B by 2025, Lebowitz tells investors.
News For GWPH From the Last 2 Days
There are no results for your query GWPH
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.